Pfizer Inc. (NYSE:PFE) Stock Position Lifted by Griffith & Werner Inc.

Griffith & Werner Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 116,596 shares of the biopharmaceutical company's stock after acquiring an additional 13,679 shares during the quarter. Pfizer makes up approximately 1.8% of Griffith & Werner Inc.'s holdings, making the stock its 21st biggest holding. Griffith & Werner Inc.'s holdings in Pfizer were worth $2,955,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter worth approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Stock Up 2.6%

PFE traded up $0.62 during trading hours on Monday, reaching $23.97. 42,513,190 shares of the stock traded hands, compared to its average volume of 41,022,920. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a market cap of $136.26 billion, a price-to-earnings ratio of 17.00, a PEG ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm's fifty day simple moving average is $22.95 and its two-hundred day simple moving average is $25.00.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. The company's revenue was down 7.8% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.18%. Pfizer's dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.